Flamel Technologies SA is a specialty pharmaceutical company utilizing core competencies in drug delivery and formulation to develop safer and more efficacious pharmaceutical products to address unmet medical needs and/or reduce overall healthcare costs.

Drug Delivery Platforms

  • Micropump®

    Modified/Controlled Release of Solid Oral Drugs

    Read more

  • LiquiTime®

    Modified/Controlled Release of Liquid Oral Drugs

    Read more

  • Trigger Lock

    Abuse-Resistant Modified/Controlled Release Narcotics/Opioid Analgesics

    Read more

  • Medusa

    Modified/Controlled Release of Injectable Drugs

    Read more


Flamel Technologies currently markets Bloxiverz and Vazculep (FDA-approved products), and develops internally products using the Unapproved Marketed Drug strategy and products based on its drug delivery platforms, and products with partners.

  • Bloxiverz website
  • Vazculep website


As a publicly-held company, Flamel Technologies strives to use its technologies to create extraordinary shareholder value.